What Is Zevra Therapeutics, Inc. (ZVRA) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Zevra Therapeutics, Inc. presents a highly debated valuation profile at its current price of $13.06. The composite intrinsic value is estimated at $13.64 (+4.4% average upside), masking a wide model spread between the 7 bullish models and 6 bearish models. Model dispersion is worth noting: Regime Cross targets $32.83 (+151.4%), versus First Chicago at $1.73 (-86.8%). This +238.1% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About ZVRA?
13 of 13 models are currently active for ZVRA. Of these, 7 models suggest upside while 6 models suggest overvaluation. The Bayesian DCF estimates ZVRA's intrinsic value at $8.27, implying -36.7% downside from the current price. See which stocks rank higher →
How Does ZVRA Rank in Pharmaceutical Preparations?
Among 469 Pharmaceutical Preparations stocks, ZVRA ranks #83 by Quality of Company score. CirclFi's QOC score of 6.6/10 evaluates 32 fundamental signals. A score of 6.6 indicates above-average quality.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a biopharma enterprise, Zevra Therapeutics, Inc. operates in a sector where biosimilar competition timeline is a critical driver of valuation. Investors evaluating ZVRA should weigh these sector-specific dynamics alongside our model-derived fair values.
Is ZVRA a Value Trap?
CirclFi's Value Trap algorithm assigns ZVRA a score of 36/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
13 of 13 models are active for Zevra Therapeutics, Inc.. Broad coverage provides high confidence. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Zevra Therapeutics, Inc.'s fundamental quality profile registers 6.6/10. This respectable score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +238.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every ZVRA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across ZVRA's 13 active models, average confidence is 36%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad